TY  - GEN
AU  - Johnson, Roch Christian
AU  - Sáez-López, Emma
AU  - Anagonou, Esaï Sèdjro
AU  - Kpoton, Godwin Gérard
AU  - Ayelo, Adjimon Gilbert
AU  - Gnimavo, Ronald Sètondji
AU  - Mignanwande, Franck Zinsou
AU  - Houezo, Jean-Gabin
AU  - Sopoh, Ghislain Emmanuel
AU  - Addo, Juliet
AU  - Orford, Lindsay
AU  - Vlasakakis, Georgios
AU  - Biswas, Nandita
AU  - Calderon, Felix
AU  - Della Pasqua, Oscar
AU  - Gine-March, Anna
AU  - Herrador, Zaida
AU  - Mendoza-Losana, Alfonso
AU  - Díez, Gabriel
AU  - Cruz, Israel
AU  - Ramón-García, Santiago
PY  - 2022
DO  - 10.1186/s13063-022-06473-9
UR  - http://hdl.handle.net/20.500.12105/15293
AB  - Background: Buruli ulcer (BU) is a neglected tropical disease caused by Mycobacterium ulcerans that affects skin, soft tissues, and bones, causing long-term morbidity, stigma, and disability. The recommended treatment for BU requires 8 weeks of daily...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Buruli ulcer
KW  - Skin neglected tropical disease
KW  - Treatment shortening
KW  - Non-inferiority
KW  - Drug combination
KW  - Amoxicillin
KW  - Clavulanate
KW  - Pharmacokinetics
KW  - Bacterial clearance
KW  - Anti-Bacterial Agents
KW  - Buruli Ulcer
KW  - Amoxicillin-Potassium Clavulanate Combination
KW  - Benin
KW  - Clarithromycin
KW  - Clinical Trials, Phase II as Topic
KW  - Humans
KW  - Multicenter Studies as Topic
KW  - Randomized Controlled Trials as Topic
KW  - Rifampin
KW  - Treatment Outcome
TI  - Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin
TY  - research article
ER  -